All Stories

  1. Author Correction: The landscape of viral associations in human cancers
  2. Whole exome sequencing study identifies candidate loss of function variants and locus heterogeneity in familial cholesteatoma
  3. Gene-Transcript Expression in Urine Supernatant and Urine Cell-Sediment Are Different but Equally Useful for Detecting Prostate Cancer
  4. Caution Regarding the Specificities of Pan-Cancer Microbial Structure
  5. Combining Molecular Subtypes with Multivariable Clinical Models Has the Potential to Improve Prediction of Treatment Outcomes in Prostate Cancer at Diagnosis
  6. Insight into the role of ‘normal’ prostate cells in prostate cancer development
  7. Whole exome sequencing study identifies candidate loss of function variants and locus heterogeneity in familial cholesteatoma
  8. APOBEC3 mutational signatures are associated with extensive and diverse genomic instability across multiple tumour types
  9. A prostate cancer patient's genetic code may be able to predict the correct treatment
  10. A potenital new test from urine for prostate cancer
  11. Microbiomes of Urine and the Prostate Are Linked to Human Prostate Cancer Risk Groups
  12. Urine risk score PUR can distinguish the aggressiveness of disease in fine detail.
  13. A new urine test for aggressive prostate cancer combining two different approaches
  14. Prostate cancer evolution from multilineage primary to single lineage metastases with implications for liquid biopsy
  15. Overlap of biological markers of prostate cancer reveals information about how progression occurs.
  16. New types of prostate cancer have been discovered and linked with how patient progress
  17. Development of a multivariable risk model integrating urinary cell DNA methylation and cell‐free RNA data for the detection of significant prostate cancer
  18. Detecting viruses in tumour tissue to discover links between cancer and infection
  19. Pan-cancer analysis of whole genomes
  20. Testing computational tools to detect bacteria and viruses in human samples of DNA
  21. Potential for diagnosis of infectious disease from the 100,000 Genomes Project Metagenomic Dataset: Recommendations for reporting results
  22. New prostate cancer urine test shows who needs treatment and when
  23. Transcriptome-Wide Effects of Sphingosine Kinases Knockdown in Metastatic Prostate and Breast Cancer Cells: Implications for Therapeutic Targeting
  24. epiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate Cancer
  25. A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer
  26. The landscape of viral associations in human cancers
  27. Detecting new potential lines of attack against prostate cancer based on genetic information
  28. Study of mechanisms to "knock out" genes in prostate cancer
  29. DESNT: A Poor Prognosis Category of Human Prostate Cancer
  30. Mutational signatures of ionizing radiation in second malignancies
  31. Prostate Single Nucleotide Polymorphism Provides a Crucial Clue to Cancer Aggression in Active Surveillance Patients
  32. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study
  33. Erratum: Corrigendum: Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue
  34. The evolutionary history of lethal metastatic prostate cancer
  35. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue
  36. Mutation detection in formalin-fixed prostate cancer biopsies taken at the time of diagnosis using next-generation DNA sequencing
  37. HES5 silencing is an early and recurrent change in prostate tumourigenesis
  38. Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer
  39. A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescue
  40. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes
  41. Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer
  42. Benzo pyrene-induced DNA adducts and gene expression profiles in target and non-target organs for carcinogenesis in mice
  43. Improved risk stratification in myeloma using a microRNA‐based classifier
  44. Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer
  45. Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study
  46. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer
  47. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer
  48. Modelling Transcription Factor Activity
  49. A Gene Expression-Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment
  50. siRNA Knockdown of Ribosomal Protein Gene RPL19 Abrogates the Aggressive Phenotype of Human Prostate Cancer
  51. A HIF-Regulated VHL-PTP1B-Src Signaling Axis Identifies a Therapeutic Target in Renal Cell Carcinoma
  52. PRKC-  Expression Promotes the Aggressive Phenotype of Human Prostate Cancer Cells and Is a Novel Target for Therapeutic Intervention
  53. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer
  54. A census of amplified and overexpressed human cancer genes
  55. Dissection of a complex transcriptional response using genome-wide transcriptional modelling
  56. Integration ofERGgene mapping and gene-expression profiling identifies distinct categories of human prostate cancer
  57. Interlaboratory and Interplatform Comparison of Microarray Gene Expression Analysis of HepG2 Cells Exposed to Benzo(a)pyrene
  58. rHVDM: an R package to predict the activity and targets of a transcription factor
  59. TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer
  60. Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance
  61. Expression profiling of CD133+and CD133-epithelial cells from human prostate
  62. Fitting ordinary differential equations to short time course data
  63. Detection of TMPRSS2-ERG Translocations in Human Prostate Cancer by Expression Profiling Using GeneChip Human Exon 1.0 ST Arrays
  64. AHR- and DNA-Damage-Mediated Gene Expression Responses Induced by Benzo(a)pyrene in Human Cell Lines
  65. Reconstructing gene networks: what are the limits?